Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death

Clinical Infectious Diseases

Volumn 47, Issue 2, 2008, Pages 198-202

  Costiniuk, Cecilia T ^a   Camacho, Fernando ^b   Cooper, Curtis L ^a,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b Damos   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; INTERFERON; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; DEATH; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER FUNCTION TEST; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; THROMBOSIS; TREATMENT OUTCOME; VIRUS HEPATITIS; VIRUS LOAD;

ADULT; ANEMIA; ANTIVIRAL AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HEMATINICS; HEMOGLOBINS; HEPATITIS C; HUMANS; INTERFERONS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 46349107968     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/589243     Document Type: Article

References (17)

1. Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 37:533-41.
2. Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005; 39(Suppl 1):S3-8.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-65.
4. Henry DH, Slim J, Lamarca A. Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection. AIDS Res Hum Retroviruses 2007; 23:1-9.
5. Dieterich DT, Wasserman R, Brau N, et al. Once weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98:2491-9.
6. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126:1302-11.
7. Maus S, Rockstroh JK. HCV/HIV-coinfection - is there a state of the art after APRICOT and RIBAVIC? J Antimicrob Chemother 2005; 56:615-8.
8. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-98.
9. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal haemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23:5960-72.
10. Wright JR, Ung YC, Julian JA, et al. Double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25:1-6.
11. Lappin TR, Maxwell AP, Johnston PG. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia. Oncologist 2007; 12:362-5.
12. Curkendall S, Richardson J, Emons M, et al. Incidence of anemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2007; 8:483-90.
13. Erslev AJ. Erythropoietin. N Engl J Med 1991; 324:1339.
14. Churchill DN, Lau C. Important safety information and new prescribing information for the erythropoiesis-stimulating agents, Aranesp® (darbopoetin alfa) and EPREX® (epoetin alfa). AMGEN Canada and Jansen-Ortho, 16 April 2007. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories- avis/prof/2007/aranesp_eprex_hpc-cps_e.html.
15. Longmore GF. Do cancer cells express functional erythropoietin receptors? N Engl J Med 2007; 356:2447.
16. Khuri FR. Weighing the hazards of erythropoietin stimulation in patients with cancer. N Engl J Med 2007; 356:2445-8.
17. Henke M, Matterson D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006; 24:4708-13.